Designing novel molecule (V-NNC) based on Voxelotor (GBT-440) against sickle cell disease (SCD) via binding to carbonmonoxy hemoglobin S

Nabati, Mehdi; Malekian, Farzaneh; Forghani, Akbar; Pournamdari, Elham; Bodaghi-Namileh, Vida

doi:10.22034/ijnc.2020.122059.1097

Designing novel molecule (V-NNC) based on Voxelotor (GBT-440) against sickle cell disease (SCD) via binding to carbonmonoxy hemoglobin S

Document Type : Research Paper

Authors

Mehdi Nabati ¹

Farzaneh Malekian ²

Akbar Forghani ¹

Elham Pournamdari ³

Vida Bodaghi-Namileh ⁴

¹ Research and Development Department, Nanogostar-e-Mihan Pharmaceutical Company, Tehran, Iran

² Research and Development Department, Shari Pharmaceutical Company, Tehran, Iran

³ Department of Science, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran

⁴ Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences,

https://doi.org/10.22034/ijnc.2020.122059.1097

Abstract

Sticking cell disease is a defect in hemoglobin structure that leads to deficiency in oxygen transferring to tissues. Voxelotor is a new compound that achieved FDA approve to treat SCD, recently. In this study, we aimed to introduce novel structure based on the voxelotor to cure the mentioned condition more effectively. At the beginning, various properties of Voxelotor including electronic properties, reactivity and stability were assessed via B3LYP/6-311++G(d,p) method and Global Reactivity in said method that revealed Voxelotor is a stable compound with low reactivity. In addition, docking potential of Voxelotor into active site of hemoglobin S was investigated. Then, several molecules were designed and optimized based on the Voxelotor structure. Docking and physicochemical properties of investigated molecules were analyzed. Results of presented study revealed that between four molecules (V-NNC, V-NNN, V-CNC and V-CNN) with higher potential to interact with Hemoglobin S in comparison with Voxelotor, only V-NNC has the optimum physicochemical features. So, molecular structure screening and evaluating of Voxelotor and designing novel compounds based on it leads to introducing an optimized molecule with suitable potential to treat SCD.

Keywords

Stricking cell disease (SCD)

Drug design

Molecular docking

Hemuglobin S

Voxelotor

[1] I. Rehman, S. Botelho, Secondary Protein Structure in Biochemistry, StatPearls Publishing, (2018).
[2] Y. Morita, T. Yamada, M. Kureishi, K. Kihira, T. Komatsu, J. Phys. Chem. B 122, 12031 (2018).
[3] R. Macdonald, M. Phillips, D. Cascio, M. Collazo, R. T. Clubb, The FASEB Journal 32, 613 (2018).
[4] J.-K. Hong, E. H. Jho, H. S. Choi, G. Kang, Sci. Total Environ. 627, 1174 (2018).
[5] M. Khoshouei, R. Danev, J. M. Plitzko, W. Baumeister, J. Mol. Biol. 429, 2611 (2017).
[6] E. Duscio, F. Vasques, F. Romitti, F. Cipulli, L. Gattinoni, J. Thorac Dis. 10, 81 (2019).
[7] M. Bellizzi and M. Bonello, J. Emerg. Med. Intens. Care 3, 1 (2018).
[8] E. I. Kvasyuk, T. I. Kulak, O. V. Tkachenko, I. A. Mikhayelopulo, A. I. Zinchenko, V. N. Barai, S. B. Bokut, S. S. Marennikova, E. V. Chekunova, Khimiko Farmatsevtichskii Zhurnal, 23, 699 (1989).
[9] J. J. Yan, T. Kroll, M. L. Baker, S. A. Wilson, R. Decréau, M. Lundberg, D. Sokaras, P. Glatzel, B. Hedman, K. O. Hodgson, Proc. Natl. Acad. Sci. 116, 2854 (2019).
[10] R. Ramachandran, C. Zhao, D. Luo, K. Wang, F. Wang, Appl. Surf. Sci. 460, 33 (2018).
[11] S. Sakurai, D. Sawada, T. Yonetani, A. Tsuneshige, Biophys. J. 110, 48a (2016).
[12] M. Rossetti, S. Ranallo, A. Idili, G. Palleschi, A. Porchetta, F. Ricci, Chem. Sci. 8, 914 (2017).
[13] B. Jensen, A. Fago, J. Inorg. Biochem. 182, 133 (2018).
[14] W. A. Eaton, E. R. Henry, J. Hofrichter, S. Bettati, C. Viappiani, A. Mozzarelli, IUBMB life 59, 586 (2007).
[15] A. Bellelli, M. Brunori, Biochim. Biophys. Acta 1807, 1262 (2011).
[16] a) W. Yan, Y. Xie, X. Wang, F. Jia, X. Li, Food Res. Int. 106, 885 (2018); b) H. Kaya, O. Hisar, S. Yılmaz, M. Gürkan, Ş. A. Hisar, Environ. Toxicol. Pharmacol. 44, 114 (2016).
[17] I. Benenson, S. Porter, Orthop. Nurs. 37, 221 (2018).
[18] S. K. Tossea, E. G. Adji, B. Coulibaly, B. A. Ako, D. N. Coulibaly, P. Joly, S.-B. Assi, A. Toure, R. Jambou, BMC Res. notes 11, 215 (2018).
[19] B. J. Kumar, A. B. Kumar, L. L. Reddy, World J. Parm. Res. 5, 328 (2016).
[20] M. Bender, GeneReviews, 2017, 1993 (2017).
[21] R. E. Ware, M. de Montalembert, L. Tshilolo, M. R. Abboud, The Lancet 390, 311 (2017).
[22] A. Habara, M. H. Steinberg, Exp. Biol. Med. 241, 689 (2016).
[23] a) E. Depetris‐Chauvin, D. N. Weil, Econ. J. 128, 1207 (2017); b) S. D. Grosse, I. Odame, H. K. Atrash, D. D. Amendah, F. B. Piel, T. N. Williams, Am. J. Prev. Med. 41, S398 (2011).
[24] B. Metcalf, C. Chuang, K. Dufu, M. P. Patel, A. Silva-Garcia, C. Johnson, Q. Lu, J. R. Partridge, L. Patskovska, Y. Patskovsky, ACS Med. Chem. Lett. 8, 321 (2017).
[25] N. M. Elmaki, I. A. Al Sadawi, A. M. Gbaj, A. Hermann, Drug. Des. Intellect. Prop. Int. J. 2, 191 (2018).
[26] M. El-Naggar, H. A. Sallam, S. S. Shaban, S. S. Abdel-Wahab, E. Amr, A. El-Galil, M. E. Azab, E. S. Nossier, M. A. Al-Omar, Molecules 24, 1066 (2019).
[27] M. Nabati, V. Bodaghi-Namileh, Int. J. New. Chem. 6, 254 (2019).
[28] M. Nabati, J. Med. Chem. Sci. 3, 22 (2020).
[29] M. Nabati, Chem. Methodol. 2, 223 (2018).
[30] M. Nabati, Iran. Chem. Commun. 7, 324 (2019).
[31] M. Nabati, H. Sabahnoo, J. Med. Chem. Sci. 2, 118 (2019).
[32] B. Metcalf, C. Chuang, K. Dufu, M. P. Patel, A. Silva-Garcia, C. Johnson, Q. Lu, J. R. Partridge, L. Patskovska, Y. Patskovsky, S. C. Almo, M. P. Jacobson, L. Hua, Q. Xu, S. L. Gwaltney, C. Yee, J. Harris, B. P. Morgan, J. James, D. Xu, A. Hutchaleelaha, K. Paulvannan, D. Oksenberg, Z. Li, ACS Med. Chem. Lett. 8, 321 (2017).
[33] M. Nabati, Asian J. Green Chem. 3, 258 (2019).
[34] M. Nabati, V. Bodaghi-Namileh, J. Phys. Theor. Chem. IAU Iran 15, 149 (2018).
[35] M. D. Esrafili, ChemistrySelect 3, 12072 (2018).
[36] H. Nazemi, M. Mirzaei, E. Jafari, Adv. J. Chem. B 1, 3 (2019).
[37] Z. S. Alidoosti, M. Mirzaei, Adv. J. Chem. B 1, 23 (2019).
[38] M. Nabati, V. Bodaghi-Namileh, Eurasian Chem. Commun. 2, 234 (2020).
[39] A. De, H. P. Ray, P. Jain, H. Kaur, N. Singh, J. Mol. Struct. 1199, 1 (2020).
[40] M. Nabati, V. Bodaghi-Namileh, J. Phys. Theor. Chem. IAU Iran 15, 159 (2018).
[41] M. Nabati, H. Sabahnoo, E. Lohrasbi, M. Mazidi, Chem. Methodol. 3, 383 (2019).
[42] M. Nabati, V. Bodaghi-Namileh, Adv. J. Chem. A 3, 58 (2020).
[43] S. Samadi, R. Ahmadi, M. Kohi, Int. J. New. Chem. 2, 8 (2015).
[44] E. Hegin, J. Shalini, A. Subramaniyan, Int. J. New. Chem. 5, 181 (2018).
[45] M. Mozafarjalali, M. Hajiani, A. Haji, Int. J. New. Chem. 7, 111 (2020).
[46] M. S. Nagar, Int. J. New. Chem. 7, 150 (2020).
[47] Z. Sarikhani, M. Manoochehri, Int. J. New. Chem. 7, 30 (2020).
[48] F. Z. Benhachem, T. Attar, F. Bouabdallah, Chem. Rev. Let. 2, 33 (2019).
[49] M. Nabati, E. Pournamdari, V. Bodaghi-Namileh, Y. Dashti-Rahmatabadi, S. Sarshar, Adv. J. Chem. B 2, 64 (2020).
[50] F. Krika, A. Krika, A. Azizi, Chem. Rev. Let. 2, 59 (2019).